Compare IFRX & PTLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFRX | PTLO |
|---|---|---|
| Founded | 2007 | 1963 |
| Country | Germany | United States |
| Employees | N/A | 7890 |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.4M | 282.8M |
| IPO Year | 2017 | 2021 |
| Metric | IFRX | PTLO |
|---|---|---|
| Price | $1.61 | $4.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 12 |
| Target Price | ★ $7.68 | $6.11 |
| AVG Volume (30 Days) | 517.1K | ★ 1.6M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $732,066,000.00 |
| Revenue This Year | N/A | $5.29 |
| Revenue Next Year | N/A | $3.97 |
| P/E Ratio | ★ N/A | $43.33 |
| Revenue Growth | N/A | ★ 3.03 |
| 52 Week Low | $0.80 | $3.29 |
| 52 Week High | $2.95 | $6.69 |
| Indicator | IFRX | PTLO |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 56.17 |
| Support Level | $1.58 | $3.79 |
| Resistance Level | $2.44 | $4.40 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 19.44 | 99.32 |
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.